

REMARKS

Applicants have amended the claims in order to reduce the initial filing fee by deleting the improper use claims 37 and 38 and by deleting the multiple dependent claims from the application. Applicants retain the right to reintroduce any subject matter canceled by the present Amendment at any time during the prosecution of this application or any further application claiming benefit of this application.

Applicants have amended the application to substitute the originally filed pages 50-66 with the amended pages 50-56 attached to the International Preliminary Examiner Report (Annexes) and included in the application as filed herewith. Also, an Abstract of the Disclosure has been added to the application.

Applicants are submitting herewith a copy of the Search Report which issued on International Application No. PCT/AU99/00724, of which the present application is the U.S. national phase. All of the publications cited in the International Search Report are listed on the attached Form PTO-1449. It is Applicants' understanding that, under the procedures of the PCT, copies of the cited publications will have been supplied to the U.S. Patent Office by the International Bureau. However, the Examiner is invited to contact the undersigned attorney if additional copies are necessary or would facilitate examination of the present application.


Otherwise, the Examiner is respectfully requested to return an initialed and dated copy of the attached Form PTO-1449 to confirm that all publications listed thereon have been considered and made officially of record in the file of this application.

Applicants understand that, under the procedures of the PCT, a copy of the priority documents (AU PP5733/98, filed 4 September 1998 and AU PQ1645/99, filed 15 July 1999) will have been supplied to the U.S. Patent Office pursuant to Rule 17 of the PCT Regulations. It is therefore respectfully requested that the first Official Action in the present application contain an indication that the appropriate priority document is in the file of this application.

U.S. National Phase of PCT/AU99/00724

In view of the above amendments, an early action on the application is now in order and is most respectfully requested.

Respectfully submitted,
BACON & THOMAS, PLLC

By: 
Richard E. Fichter
Registration No. 26,382

625 Slaters Lane - 4th Floor
Alexandria, Virginia 22314
Phone: (703) 683-0500
Facsimile: (703) 683-1080

REF:kdd
PA01.wpd

DATE: March 2, 2001

U.S. National Phase of PCT/AU99/00724

Version with Markings to Show Changes Made

7. (Amended) A method according to claim 1 [or 5] wherein the MPV is an HPV.

20. (Amended) A method according to [any one of] claim[s] 14 [to 19] wherein any -CH₂- group of formula (a) is optionally substituted by one or more of the groups selected from methyl, ethyl, n-propyl, iso-propyl, hydroxy, halo, methoxy, ethoxy, iso-propoxy, acetoxy, optionally substituted benzyl, optionally substituted pyridyl, optionally substituted pyrimidyl and optionally substituted phenyl.

34. (Amended) A method according to claim 13 [or 33] wherein the compound is capable of effecting at least 30% zinc release in a TSQ assay and/or inhibits or reduces the binding of an E6 protein to E6AP or E6BP and/or exhibits selective cytotoxicity towards MPV-infected cells.

35. (Amended) A method according to claim 13 [or 33] wherein the disease or condition is cervical cancer or its HPV associated precursor lesions or any other HPV associated cancers and/or warts.